UCB announced today that NAYZILAM® (midazolam) nasal spray CIV will be available in retail pharmacies on December 2, 2019, for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
Pediatric Epilepsy
Despite orphan designations for rare epilepsies having dramatically increased in the past 10 years, the number of approved drugs remains limited and restricted to a handful of epilepsy syndromes.
Pediatric Epilepsy
Children with early onset of febrile seizures and especially those with recurrent febrile seizures may be at heightened risk for poorer verbal and processing speed functioning and hence at risk of acquiring cognitive, executive dysfunctions.
To help Californians receive the highest level of care regardless of where they live, epilepsy experts have established the USC Epilepsy Care Consortium.
A pair of researchers have created an AI system that can predict epileptic seizures with 99.6-percent accuracy.
The results of the study demonstrated that adjunctive treatment with cenobamate produced significant reductions in seizures compared to placebo.
Researchers from the University of California, Irvine developed a breakthrough cell therapy to improve memory and prevent seizures in mice following traumatic brain injury.
From 70 years of experience with epilepsy surgery, science now has a richer understanding of the clinical, neuroimaging, and surgical predictors of memory decline-and improvement-after TLR.
